Core Points - Addex Therapeutics will release its Q1 2024 financial results on June 6, 2024, and will provide a business update and product pipeline review during a teleconference and webcast [1] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on the same day [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, ADX71149, is a positive allosteric modulator (PAM) for mGlu2 and has completed a Phase 2 clinical study for epilepsy [3] - The second clinical program, dipraglurant, is a negative allosteric modulator (NAM) for mGlu5, under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior to advance multiple drug candidates for substance use disorder and is also developing a GABAB PAM program for chronic cough [3] - The company holds a 20% share in Neurosterix LLC, which is advancing several allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analys ...

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recen ...

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recent develop ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Phase 2 study did not ac ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all particip ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECT ...

EXHIBIT 99.1 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX ...

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery ...

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 0 ...